Specific anti-PD-L1 antibody can reduce the expression of sPD-L1 and remove its blocking effect on PD-1/PD-L1 negative signaling pathway, which may help to improve T cell viability and enhance the killing for breast cancer cells. Here, SPDL1 is linked to breast carcinoma.